ISDIN Report issue

For profit Phase 2
Founded: Barcelona Spain (1975)
Status: No NME R&D (1975)

Organization Overview

First Clinical Trial
2007
NCT00656825
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 2)

Psoriasis (Phase 2)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 5